Deepmatter Group helping to make drugs 'faster, cheaper and more cost effectively'

DeepMatter Group PLC's (LON:DMTR) Mark Warne introduces the business to Proactive London's Andrew Scott and talks through the firm's interim results to June 2019.

''What we're trying to do is address a $28bn problem to improve re-produceability in science so ultimately drugs can be made faster, cheaper and more cost-effectively''

''The business was spun out of the University of Glasgow at the back end of 2014, we've grown our Deepmatter platform over the last two or three years .... and now we're generating our first revenues''.

deepmatter,mark warne,